HIGHLIGHTS
- who: Elisa Del Savio and Roberta Maestro from the National Cancer Institute, Aviano, PN, Italy have published the article: Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma, in the Journal: Cells 2022, 11, x FOR PEER REVIEW of 30/06/2022
- what: The study showed advanced solid tumors or with B-cell lymphomas was launched . The study showed that tazemetostat had a safety profile and showed antitumor activity in a subset of pathat tazemetostat had a safety profile and showed antitumor activity in a subset of patients tients that included ES.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.